Unigene Laboratories : Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9

Investors & Media

Home

«  back to releases

• Corporate Profile
• Stock Quote
• Press Releases
• Events
• Financial Reports
• SEC Filings
• Governance
• Investor Kit
• Analysts Coverage

Investor Contact:

Jenene Thomas
Vice President, Investor Relations and Business Administration

[e-mail]

Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9

January 4, 2012 - Boonton, NJ - Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will present a corporate overview at the Biotech Showcase™ 2012 in San Francisco, CA on Monday, January 9, 2012 at 11:30 a.m. PT (2:30 p.m. ET). Mr. Palmer's presentation will include an overview of Unigene's industry-leading oral peptide delivery platform and pipeline along with the Company's business outlook and expected milestones for 2012. A live webcast of the presentation will be available by visiting the Investors and Media section under the Events tab of the Unigene web site, http://www.unigene.com. Participants should allow approximately 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days. About Unigene Laboratories, Inc. Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies. Investor Contact:Unigene Laboratories, Inc. Jenene Thomas VP, Investor Relations and Business Administration 973-265-1107 [e-mail] Media Contact: Tiberend Strategic Advisors, Inc. Jason Rando / Andrew Mielach 212-827-0020 [e-mail] / [e-mail]